Key Highlights

• NDRA shares closed 31.42% lower at $4.30 on June 25, falling from the previous close of $6.27.

• Existing ENDRA shareholders are expected to own approximately 3% of the combined Noble Africa company.

• A concurrent $50 million private placement supports helium project development but adds further dilution and transaction risk.

Noble Africa Merger Terms Drive NDRA Selloff

ENDRA Life Sciences Inc. (NASDAQ: NDRA) shares closed 31.42% lower at $4.30 on June 25, 2026, after the company announced a proposed merger involving Noble Africa, a subsidiary of ASP Isotopes.

The decline appears to reflect concerns over the transaction’s ownership structure and the major change in ENDRA’s business direction.

Under the proposed agreement, Noble Africa will merge with an ENDRA subsidiary and remain the surviving entity. The combined company plans to operate as Noble Africa Inc. and apply to trade on Nasdaq under the ticker NOBA.

ASP Isotopes is expected to own approximately 89% of the combined company. Investors participating in a concurrent private placement, excluding ASP Isotopes, would own about 7%, while ENDRA’s existing shareholders would retain approximately 3%.

Ownership Dilution Resets the Valuation

The expected 3% ownership allocation is the most significant issue for ENDRA shareholders.

Although the merger gives investors exposure to Noble Africa and Renergen’s Virginia Gas Project, existing owners would hold only a small economic interest in the combined business.

The transaction therefore represents more than a conventional acquisition. It effectively replaces ENDRA’s medical-technology investment thesis with exposure to a helium and natural-gas development platform.

ENDRA currently develops Thermo Acoustic Enhanced UltraSound technology for measuring liver fat and monitoring tissue ablation. Following the proposed merger, the combined company would instead focus primarily on Renergen’s helium operations in South Africa.

This strategic pivot may create long-term optionality, but it also introduces mining, energy, commodity-price and project-development risks that differ substantially from ENDRA’s existing healthcare profile.

$50 Million Financing Supports Development

Noble Africa has secured commitments for a private placement expected to generate approximately $50 million in gross proceeds.

ASP Isotopes plans to invest about $20 million, while other investors are expected to provide roughly $30 million. Certain ASP Isotopes directors and executives are contributing $750,000.

The financing is intended to support Phase 1 and Phase 2 development of the Virginia Gas Project and is expected to close immediately before the merger.

Fresh capital may improve Noble Africa’s ability to advance the project, but the financing also expands the ownership base and reduces the percentage allocated to existing ENDRA investors.

Transaction Remains Conditional

The proposed merger has received approval from the boards of ENDRA and ASP Isotopes. Completion is expected during the third or fourth quarter of 2026.

However, the transaction remains subject to several conditions, including ENDRA shareholder approval, an effective SEC registration statement, financing completion and customary closing requirements.

There is also no assurance that the combined company will receive or maintain Nasdaq listing approval under the proposed NOBA ticker.

At the June 25 close, ENDRA had an indicated market capitalisation of approximately $3.2 million. The company’s small size and limited trading liquidity may have amplified the percentage decline.

Conclusion

ENDRA’s 31.42% closing decline reflects investor concern over the economic terms of the Noble Africa merger.

The transaction provides access to a potentially valuable helium development asset and approximately $50 million of new financing. However, existing ENDRA shareholders are expected to retain only about 3% of the combined company while assuming exposure to a new and capital-intensive industry.

The next valuation tests will be the merger filing, shareholder vote, final financing terms and further disclosure on the value assigned to ENDRA investors.